Business Daily Media

Business Marketing

.

Biogen Completes Submission of Biologics License Application to FDA for Aducanumab as a Treatment for Alzheimer's Disease

  • Written by ACN Newswire - Press Releases

Biogen Completes Submission of Biologics License Application to FDA for Aducanumab as a Treatment for Alzheimer's Disease

TOKYO, Jul 9, 2020 - (JCN Newswire) - Biogen (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today announced that Biogen has completed the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the approval of aducanumab, an investigational treatment for Alzheimer's disease. The completed

Read more //?#

Popular

Purpose Conference, Australia’s largest purpose-driven business event

BRACE FOR IMPACT: THE NATION’S BIGGEST PURPOSE-DRIVEN BUSINESS EVENT RETURNS Super Early Bird ticket allocation already snapped up Early bird tickets are now on sale Purpose Conference, Australia’s largest purpose-drive...

How to find yourself the perfect lawyer for a separation agreement

There are some people out there who are currently ending their relationship. While this is often for the best, it can come along with a whole host of new things to think about. For instance, even if people aren’t married they ...

Akaysha Energy wins agreement to build four hour battery energy storage system

Akaysha Energy has signed a Long-Term Energy Service Agreement which will support the build and operation of a groundbreaking 415MW/1660MWh utility-grade battery energy storage system under a competitive tender from AEMO Servi...